Skip to main content
. 2019 Jul 23;10:1707. doi: 10.3389/fimmu.2019.01707

Figure 5.

Figure 5

Effect of rFgCatB protein on PBMC viability. Goat PBMCs were treated with PBS or with serial concentrations of rFgCatB protein and incubated for 48 h at 37°C at 5% CO2. Viability of cells was determined using CCK-8 assay. Results indicate that rFgCatB protein significantly reduced the viability of PBMCs in a dose-dependent manner. Graphs represent means ± standard deviations of data from three independent biological replicates (10 μg/ml: ANOVA, F(5, 12) = 28.50, P = 0.0007; 20 μg/ml: ANOVA, F(5, 12) = 28.50, P = 0.0035; 40 μg/ml: ANOVA, F(5, 12) = 28.50, P = 0.0015; 80 μg/ml: ANOVA, F(5, 12) = 28.50, P < 0.0001; 160 μg/ml: ANOVA, F(5, 12) = 28.50, P < 0.0001). Asterisks indicate significant differences between rFgCatB-treated and PBS-treated control cells (**P < 0.01; ***P < 0.001; ****P < 0.0001 compared with control).